Radiotherapy meets anticancer metallodrugs

Area of Science:

• Oncology
• Radiochemistry
• Materials Science

Background:

• Combined radiotherapy and chemotherapy are standard cancer treatments.
• Metallodrugs, particularly platinum agents, are crucial but face toxicity and selectivity issues.
• Advances in radiation and metal chemistry enable new therapeutic strategies.

Purpose of the Study:

• To explore the intersection of radiotherapy and metallodrugs.
• To highlight how radiation can activate and modulate metallodrugs.
• To discuss the potential for enhanced cancer treatment through this synergy.

Main Methods:

• Reviewing strategies where radiation activates metallodrugs.
• Examining platinum prodrugs, non-platinum metal complexes, and high-Z materials.
• Discussing radiometal-based drugs integrating radiochemistry and coordination chemistry.

Main Results:

• Ionizing radiation can activate, modulate, or amplify metallodrug function in tumors.
• Radiation energy can achieve spatially confined cytotoxicity and immune modulation.
• Synergistic tumor control is achievable through the integration of radiotherapy and metallodrugs.

Conclusions:

• The combination of radiotherapy and metallodrugs offers enhanced, targeted cancer treatment.
• Radiometal-based drugs represent a key development at the intersection of these therapies.
• This integrated approach holds significant promise for clinical oncology.